Global Paclitaxel for Injection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Paclitaxel for Injection Market Research Report 2024
Paclitaxel Injection is a kind of anti-cancer injection taking paclitaxel API as raw material. It is mainly used in breast cancer, ovarian cancer and other cancers.
Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks.
According to Mr Accuracy reports’s new survey, global Paclitaxel for Injection market is projected to reach US$ 7025.7 million in 2029, increasing from US$ 3384 million in 2022, with the CAGR of 11.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Paclitaxel for Injection market research.
Paclitaxel injection is a chemotherapy drug used to treat many types of cancer. It is mainly used as an anti-tumor drug, and has a wide range of applications in the treatment of ovarian cancer, breast cancer, non-small cell lung cancer and gastrointestinal tumors. Its market overview is as follows
a. Market demandWith the increase in the number of cancer patients, the demand for anti-tumor drugs is also increasing. Paclitaxel injection, as a commonly used antitumor drug, has been widely recognized and used by clinicians and patients.
b. Market competitionThere are other similar anti-tumor drugs on the market, such as paclitaxel injection. Although these drugs have some overlap in the treatment of cancer, there may be differences in specific applications and effects. Therefore, paclitaxel injection also needs to face market competition pressure from competitors.
c. Market sizeThe market size of Paclitaxel injection is relatively large. With the continuous progress of clinical research and the emergence of new treatment options, the market size is expected to continue to grow.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Paclitaxel for Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Getwell Pharmaceuticals
CSPC Pharmaceutical Group Limited
AdvaCare Pharma
Pfizer
Bristol-Myers Squibb
Celgene Corporation
Hospira
Biological E.
Taj Accura
Luye Pharma
Youcare Pharmaceutical
Hainan Chuntch Pharmaceutical Co Ltd
Healthiza Lifescience Private Limited
Beijing Union Pharmaceutical Factory
Hengrui Pharmaceuticals
Qilu Pharmaceutical Co., Ltd.
Hainan Haiyao
Segment by Type
5ml,30mg
10ml,60mg
16.7ml,100mg
25ml,150mg
50ml,300mg
Ovarian Cancer
Breast Cancer
Cervical Cancer
Pancreatic Cancer
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Paclitaxel for Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks.
According to Mr Accuracy reports’s new survey, global Paclitaxel for Injection market is projected to reach US$ 7025.7 million in 2029, increasing from US$ 3384 million in 2022, with the CAGR of 11.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Paclitaxel for Injection market research.
Paclitaxel injection is a chemotherapy drug used to treat many types of cancer. It is mainly used as an anti-tumor drug, and has a wide range of applications in the treatment of ovarian cancer, breast cancer, non-small cell lung cancer and gastrointestinal tumors. Its market overview is as follows
a. Market demandWith the increase in the number of cancer patients, the demand for anti-tumor drugs is also increasing. Paclitaxel injection, as a commonly used antitumor drug, has been widely recognized and used by clinicians and patients.
b. Market competitionThere are other similar anti-tumor drugs on the market, such as paclitaxel injection. Although these drugs have some overlap in the treatment of cancer, there may be differences in specific applications and effects. Therefore, paclitaxel injection also needs to face market competition pressure from competitors.
c. Market sizeThe market size of Paclitaxel injection is relatively large. With the continuous progress of clinical research and the emergence of new treatment options, the market size is expected to continue to grow.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Paclitaxel for Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Getwell Pharmaceuticals
CSPC Pharmaceutical Group Limited
AdvaCare Pharma
Pfizer
Bristol-Myers Squibb
Celgene Corporation
Hospira
Biological E.
Taj Accura
Luye Pharma
Youcare Pharmaceutical
Hainan Chuntch Pharmaceutical Co Ltd
Healthiza Lifescience Private Limited
Beijing Union Pharmaceutical Factory
Hengrui Pharmaceuticals
Qilu Pharmaceutical Co., Ltd.
Hainan Haiyao
Segment by Type
5ml,30mg
10ml,60mg
16.7ml,100mg
25ml,150mg
50ml,300mg
Segment by Application
Ovarian Cancer
Breast Cancer
Cervical Cancer
Pancreatic Cancer
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Paclitaxel for Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices